Program
ofirnoflast
Also written as “HT-6184” and “Ofirnoflast”.
Its studies are mostly in Myelodysplastic Syndromes · Diabetes Mellitus, Type 2 · Pain, led by Halia Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Halia Therapeutics | 51 open or running | phase 2since Jan 15, 2024 | May 19, 2022 | Oct 2028phase 2 · NCT07738510 |
Also a collaborator on its studies: parexel and tkl-research-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 19, 2022First study: phase 1 study in Normal Healthy SubjectsFirst studyNCT05447546 · 64 enrolled · United States
- Jan 15, 2024Phase 2 study in PainNCT06241742 · 81 enrolled · United States
- Jun 26, 2025Phase 2 study in Myelodysplastic SyndromesNCT07052006 · 37 enrolled · India
- Aug 25, 2025Phase 2 study in Diabetes Mellitus, Type 2NCT07172867 · United Arab Emirates
- Jul 27, 2026Phase 2 study in Myelodysplastic SyndromesNCT07738510 · 70 planned · United States
Ahead
- Oct 2028Primary completion: phase 2 study in Myelodysplastic SyndromesNCT07738510
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07738510Myelodysplastic Syndromes · United States | 2 | Not yet recruiting | Oct 2028 | 70 |
| NCT07172867Diabetes Mellitus, Type 2 · United Arab Emirates | 2 | Withdrawn | Jan 23, 2026 | 0 |
| NCT07052006Myelodysplastic Syndromes · India | 2 | Completed | Jan 8, 2026 | 37 |
| NCT06241742Pain · United States | 2 | Completed | Apr 30, 2024 | 81 |
| NCT05447546Normal Healthy Subjects · United States | 1 | Completed | Jul 20, 2023 | 64 |
How it is read
Names in the registry
- “HT-6184”, 4 entries
- “Ofirnoflast”, 1 entry
Conditions, from the studies’ own filings
- Myelodysplastic Syndromes, 2 studies
- Diabetes Mellitus, Type 2, 1 study
- Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.